Sotera Health (SHC) fundamentals: P/E, valuation, undervalued?
Sotera Health · Health Care · ref. ETF XLV · price $19.48
In short — Sotera Health trades at 34.2× earnings (P/E), 18.1× forward, with a net margin of 13.4 % and revenue growth of +9 %. Read: Cheap for the growth (P/E 18 for ~570% growth (PEG 0.0)).
Is Sotera Health stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$19.48+20.2% over range
Aug 28, 25low $13.13 · high $19.57Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
80% recommend buying · 5 analysts
Valuation : Cheap for the growth — P/E 18 for ~570% growth (PEG 0.0)
Valuation
34.2
P/E (price/earnings)
18.1
Forward P/E
—
PEG
8.3
Price/book (P/B)
$5.6B
Market cap
0.57
EPS
Profitability & growth
13.4 %
Net margin
+9 %
Revenue growth
+570 %
Earnings growth
$2.3B
Total debt
Sotera Health income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.0B | $-234M | -23.3 % |
| 2023 | $1.0B | $51M | 4.9 % |
| 2024 | $1.1B | $44M | 4.0 % |
| 2025 | $1.2B | $78M | 6.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Sotera Health's P/E and is the stock undervalued? What's a good P/E?
Sotera Health's P/E is 34.2 (forward 18.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Sotera Health profitable?
Sotera Health has a net margin of 13.4 % (EPS 0.57). The company is profitable.
Is SHC stock expensive?
Our read: "Cheap for the growth" — P/E 18 for ~570% growth (PEG 0.0). Cross-check with growth and sector.
💬 A question about Sotera Health? The JPI assistant answers using our backtest data.
Keep exploring Sotera Health